Effectiveness of pertussis vaccination in pregnancy to prevent hospitalisation in infants aged <2 months and effectiveness of both primary vaccination and mother's vaccination in pregnancy in infants aged 2-11 months |
| |
| Affiliation: | 1. Epidemiology Department, Epiconcept, Paris, France;2. Public Health Agency of Catalonia (ASPCAT), Barcelona, Spain;3. Universitat Politècnica de Catalunya- BarcelonaTech (UPC), Barcelona, Spain;4. Children’s Health Ireland, Crumlin, Dublin, Ireland;5. Instituto de Salud Pública de Navarra, IdiSNA – Navarre Institute for Health Research, Pamplona, Spain;6. Multifactorial Disease and Complex Phenotype Research Area, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy;7. National Institute of Public Health, Prague, Czech Republic;8. Institut de Recerca Sant Joan de Déu, Hospital Sant Joan de Déu, Barcelona, Spain;9. CIBER of Epidemiology and Public Health (CIBERESP), Barcelona, Spain;10. University of Barcelona, Barcelona, Spain;11. Health Protection Surveillance Centre, Dublin, Ireland;12. Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy;13. Sorbonne University, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, Paris, France;14. Medicine Department, Universitat Internacional de Catalunya, Barcelona, Spain;15. European Centre for Diseases Control and Prevention, Stockholm, Sweden |
| |
| Abstract: | BackgroundPERTINENT is an active hospital-based surveillance system for pertussis in infants. In 2019, four of the six participating European countries recommended pertussis vaccination in pregnancy. Among infants aged <2 months, we measured the vaccine effectiveness (VE) in pregnancy; among infants aged 2–11 months, VE of vaccination in pregnancy and of primary vaccination (PV).MethodsFrom December 2015 to 2019, we included all infants aged <1 year presenting with pertussis-like symptoms. Using a test-negative-design, cases were infants testing positive for Bordetella pertussis by PCR or culture. Controls were those testing negative for all Bordetella species. Vaccinated mothers were those who received vaccine in pregnancy. Vaccinated infants were those who received ≥1 dose of PV > 14 days before symptom onset. We excluded infants with unknown maternal or PV status or with mothers vaccinated ≤14 days before delivery. We calculated pooled VE as 100 * (1-odds ratio of vaccination) adjusted for study site, onset date in quarters and infants’ age group.ResultsOf 829 infants presenting with pertussis-like symptoms, 336 (41%) were too young for PV. For the VE in pregnancy analysis, we included 75 cases and 201 controls. Vaccination in pregnancy was recorded for 9 cases (12%) and 92 controls (46%), adjusted VE was between 75% [95%CI: 35–91%] and 88% [95%CI: 57–96%].Of 493 infants eligible for PV, we included 123 cases and 253 controls. Thirty-one cases and 98 controls recorded both PV with ≥ 1 dose and vaccination in pregnancy, adjusted VE was between 74% [95%CI: 33–90] and 95% [95%CI: 69–99]; 27 cases and 53 controls recorded PV only, adjusted VE was between 68% [95%CI: 27–86] and 94% [95%CI: 59–99].ConclusionOur findings suggest that vaccination in pregnancy reduces pertussis incidence in infants too young for PV. In infants aged 2–11 months, PV only and both PV and vaccination in pregnancy provide significant protection against severe pertussis. |
| |
| Keywords: | Pertussis Vaccine effectiveness Vaccine in pregnancy Whooping cough Hospital surveillance PV" },{" #name" :" keyword" ," $" :{" id" :" k0035" }," $$" :[{" #name" :" text" ," _" :" primary vaccination PERTINENT" },{" #name" :" keyword" ," $" :{" id" :" k0045" }," $$" :[{" #name" :" text" ," _" :" Pertussis in Infants European Network |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
